drug
tipranavir
Marketedupdated 3mo agoby Boehringer Ingelheim Corp
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying tipranavir
- phase1Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency
- phase1Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment
- phase23 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study
- phase2Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that